Skip to content
OpenCapital
Get started

Edwards Lifesciences EW Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Automatic Data Processing, Inc. logo
Automatic Data Processing, Inc.ADP
$2.93B+133%
General Motors logo
General MotorsGM
$2.85B+167%
Edwards Lifesciences logo
Edwards LifesciencesEW
$710.1M-14.2%
ServiceNow logo
ServiceNowNOW
$1.14B-3.6%
Equitable Holdings logo
Equitable HoldingsEQH
$2.76B-38.2%
Atlantic Union Bankshares logo
Atlantic Union BanksharesAUB
$80.14M+93.7%

Other financials

Income statement

See full
Revenue$1.6B+16.7%
Gross profit$1.3B+15.7%
Operating income$477.6M+21.0%
Net income$380.7M+6.3%
EPS (diluted)$0.66+8.2%

Balance sheet

See full
Cash & equivalents$2.4B-22.3%
Total debt$702.9M+0.5%
Total equity$10.3B+2.0%
Total assets$13.3B+2.3%

Cash flow

See full
Operating cash flow$43.8M-84.4%
CapEx$64.9M+15.9%
Free cash flow-$21.1M-109%

Valuation

See full
Market cap$52.09B+20.1%
Enterprise value$50.34B+23.3%
P/E47.5×+37.1×
P/S8.3×+0.6×

Profitability

See full
Gross margin77.9%-1.6pp
Operating margin21.4%-4.4pp
Net margin17.4%-58.3pp
FCF margin17.3%—

Returns & leverage

See full
Return on equity10.7%-37.8pp
Debt / equity0.1×0.0×
Current ratio4.4×0.0×

Where this comes from

Reported directly by Edwards Lifesciences in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Edwards Lifesciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edwards Lifesciences's proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edwards Lifesciences's proceeds from sale and maturity of available for sale securities?
Edwards Lifesciences (EW) reported proceeds from sale and maturity of available for sale securities of $710.1M in Q1 2026.
How has Edwards Lifesciences's proceeds from sale and maturity of available for sale securities changed year-over-year?
Edwards Lifesciences's proceeds from sale and maturity of available for sale securities decreased by 14.2% year-over-year, from $827.9M to $710.1M.
What is the long-term trend for Edwards Lifesciences's proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), Edwards Lifesciences's proceeds from sale and maturity of available for sale securities has grown at a 63.8% compound annual growth rate (CAGR), from $391.2M to $2.82B.
What does proceeds from sale and maturity of available for sale securities mean?
Cash inflows generated from the sale or maturity of available-for-sale debt or equity securities. This reflects the company's ability to liquidate portions of its investment portfolio to meet cash needs.